A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.

Also called NCT02390050

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 292 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02390050
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02390050. Randomized; quadruple masking; primary purpose treatment. Start 2015-05-12 (actual); primary completion 2016-06-03 (actual). Results posted on 2021-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Bexagliflozin tablets
Intervention (Drug)
Bexagliflozin tablets, placebo
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct02390050
Content hash
fa6f37535ebcc1a9d36bced48d34e3944bd16f74d016e7217c5fae3ffefa176c